Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 13,625 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Reading of Automated Breast Ultrasound in conjunction with Screening Mammography; Device
Lead sponsor: Delphinus Medical Technologies, Inc.; Industry
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: BSI-045B; Drug
Lead sponsor: Biosion, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 17
States / cities: Fountain Valley, California • Fremont, California • Oceanside, California + 14 more

Conditions: Giant Cell Arteritis
Interventions: Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Boca Raton, Florida • Gainesville, Florida • Iowa City, Iowa + 3 more

Conditions: Melanoma
Interventions: Observation, Radiation Therapy; Other · Radiation
Lead sponsor: Melanoma and Skin Cancer Trials Limited; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Breast Cancer
Interventions: Zoledronic acid, Physical activity intervention; Drug · Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: 40 Years to 55 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Saint Louis Park, Minnesota

Conditions: Psoriasis
Interventions: ustekinumab, placebo; Drug
Lead sponsor: Centocor Research & Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more

Conditions: Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
Interventions: etrasimod, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 44
States / cities: Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 17 more

Conditions: Atopic Dermatitis
Interventions: YR001 ointment, Placebo; Drug · Other
Lead sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Boynton Beach, Florida • Hollywood, Florida • Weston, Florida + 1 more

Conditions: Diabetic Foot Ulcer
Interventions: Esmolol hydrochloride, Placebo gel; Drug
Lead sponsor: Novalead Pharma Private Limited; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Skin Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 1,889 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2026
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Harrison, New York • Hauppauge, New York + 1 more

Conditions: Breast Cancer
Interventions: Omega-3 Supplementation; Dietary Supplement
Lead sponsor: Lauren Nye; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Westwood, Kansas

Conditions: Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions: Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Vitiligo
Interventions: Etanercept; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Pruritus
Interventions: Dupilumab, Placebo, Fexofenadine (loratadine if not available); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Bakersfield, California • La Jolla, California • Washington D.C., District of Columbia + 16 more

Conditions: Medical Oncology
Interventions: BAY1217389, Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Cellulitis
Interventions: teledermatology consult, Routine Care; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide; Drug
Lead sponsor: Shire; Industry
Eligibility: 16 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 40
States / cities: Little Rock, Arkansas • Bell Gardens, California • Granada Hills, California + 35 more

Conditions: Herpes Simplex
Interventions: Neem Based External Application Cream; Other
Lead sponsor: Southern California University of Health Sciences; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Whittier, California

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Uveal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma
Interventions: vorinostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Rockledge, Pennsylvania

Conditions: Breast Cancer, Lymph Node Mapping, Sentinel Lymph Node Biopsy
Interventions: IC2000 and SPY-PHI, Tc-99m radioactive colloid and Gamma Probe; Combination Product
Lead sponsor: Novadaq Technologies ULC, now a part of Stryker; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 2 more

Conditions: Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
Interventions: Ionizing radiation (IR) therapy, Ionizing radiation (IR); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Melanoma
Interventions: Ipilimumab; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Cancer, Breast Cancer
Interventions: Whey protein (20 grams), Whey protein (60 grams); Dietary Supplement
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 20 Years to 89 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hodgkin's Disease, Breast Cancer
Interventions: Tamoxifen; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

Delphinus SoftVue™ ROC Reader Study

POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Neurotropic Melanoma of the Head and Neck

Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin

Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

Effect of Teledermatology on Length of Hospital Admission, Length of Stay, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic ED Setting

Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

Effectiveness of TheraNeem Lip Therapy for Herpes Simplex Labialis

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox

Resistance Training and Post Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors